

ACR Appropriateness Criteria[®]

Management of Uterine Fibroids:

2023 Update

Expert Panel on Interventional Radiology: *Mina S. Makary, MD^a, Kylie Zane, MD^b, Gloria L. Hwang, MD^c, Charles Y. Kim, MD^d, Osmanuddin Ahmed, MD^e, Erica M. Knavel Koepsel, MD^f, Eric J. Monroe, MD^f, Matthew J. Scheidt, MD^g, Amanda R. Smolock, MD, PhD^g, Elizabeth A. Stewart, MD^h, Ashish P. Wasnik, MDⁱ, Jason W. Pinchot, MD^j*

Abstract

Uterine fibroids are the most common benign tumor in women of reproductive age and can present with symptoms including bleeding, bulk related symptoms, and infertility. Several treatment options are available for the management of uterine fibroids, including medical management, minimally invasive therapies such as uterine artery embolization and MR-guided focused ultrasound

^aOhio State University Wexner Medical Center, Columbus, Ohio.

^bResearch Author, University of Chicago Hospitals, Chicago, Illinois.

^cStanford University School of Medicine, Stanford, California.

^dPanel Chair, Duke University Medical Center, Durham, North Carolina.

^eUniversity of Chicago, Chicago, Illinois.

^fUniversity of Wisconsin, Madison, Wisconsin.

^gFroedtert & The Medical College of Wisconsin, Milwaukee, Wisconsin.

^hMayo Clinic and Mayo Clinic Alix School of Medicine; American College of Obstetricians and Gynecologists.

ⁱUniversity of Michigan, Ann Arbor, Michigan.

^jSpecialty Chair, University of Wisconsin, Madison, Wisconsin.

Corresponding author: Mina S. Makary, MD, 2978 E Powell Road, Columbus, OH 43240; e-mail: minamakary1@hotmail.com.

The ACR seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels. Participation by representatives from collaborating societies on the expert panel does not necessarily imply individual or society endorsement of the final document.

Reprint requests to: publications@acr.org.

Dr Ahmed reports grants or contracts from Research grant from Canon Medical; consulting fees from Canon Medical, Penumbra, Angiodynamics, Asahi, Philips, Boston Scientific, Medtronic, Johnson and Johnson; payments or honoraria from Penumbra; other from CMO and equity owner (co-founder) of Flow Medical. Dr Kim reports consulting fees from Boston Scientific, Baylis, ACI/Humacyte, Beckton Dickinson. Dr Knavel Koepsel reports participation on an advisory board for Boston Scientific Medical Advisory Board 2023 and 2024; leadership roles as Director: Interventional MRI Program at University of Wisconsin. Dr Monroe reports leadership roles as Board of Directors, Society of Pediatric Interventional Radiology. Dr Pinchot reports leadership roles as ACR-

Subspecialty Chair, Vascular and Interventional Radiology. Dr Scheidt reports leadership roles as SIO Education Committee Steering Committee. Dr Smolock reports grants or contracts from RSNA R&E Foundation Grant, NeuWave Medical; payments or honoraria from NeuWave Medical consultant/speaking faculty, The France Foundation, HMP Education; participation on an advisory board for AstraZeneca, HistoSonics Inc, Varian Medical; leadership roles as SIO, Chair, AstraZeneca CME project; stock in HistoSonics Inc, Boston Scientific; other from HistoSonics Inc, Elucet Medical, Boston Scientific - Note: Disclosures for Dr Smolock include time period of manuscript preparation. Dr Smolock is an employee of Boston Scientific at time of publication. Dr Stewart reports grants or contracts from NIH: P50HS23418, R01HD105714, R01HD109127-01A1 and P50HD115283 all paid to Mayo Clinic; royalties or licenses from UpToDate paid to me; consulting fees from AbbVie, Alnylam, paid to me; payments or honoraria from MED-IQ<Omnia, Omnicur, Physicians Educational Resources, Web MD All paid to me for Peer reviewed CME; patents from Methods and Compounds for Treatment of Abnormal Uterine Bleeding 6440445, Issued but no royalties; participation on an advisory board for Myovant paid to me; leadership roles as Treasurer of the International Gynecologic Society, unpaid; other from Unpaid advisor to Fibroid Foundation. Dr Wasnik reports grants or contracts from Unrelated: Research grant through University of Michigan from National Institute Health & Sequana Medical Inc; royalties or licenses from Royalty (book), Elsevier Inc, Royalty, IP Applied Morphomics Inc; patents from US Patent 10,918,326. Dr Pinchot is a partner; and the other authors are non-partner/non-partnership track/employees.

The ACR Appropriateness Criteria documents are updated regularly. Please go to the ACR website at www.acr.org/ac to confirm that you are accessing the most current content.

Disclaimer: The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists, and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other coexistent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.

ablation, and surgical interventions ranging from laparoscopic myomectomy to open hysterectomy. Given this wide range of therapeutic interventions, it is important to understand the data supporting these interventions and to be able to apply it in different clinical settings. This document provides a summary of recent trials supporting various therapies for uterine fibroids, including recent evidence for MR-guided focused ultrasound ablation and a detailed discussion of fertility outcomes in myomectomy and uterine fibroid embolization.

The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation.

Key Words: Appropriateness Criteria, appropriate use criteria, AUC, MRgFUS, MR-guided high-frequency focused ultrasound ablation, UAE, uterine artery embolization, UFE, uterine fibroid embolization

J Am Coll Radiol 2024;21:S203-S218. Copyright © 2024 American College of Radiology

ACR Appropriateness Criteria® Management of Uterine Fibroids: 2023 Update. Variants 1 to 6 and Table 1.

Variant 1. Reproductive age patient with uterine fibroids, symptomatic with heavy uterine bleeding or bulk symptoms (eg, pressure, pain, fullness, bladder, or bowel symptoms), and a desire to preserve fertility. Initial therapy.

Procedure	Appropriateness Category
Hysteroscopic myomectomy	Usually Appropriate
Laparoscopic or open myomectomy	Usually Appropriate
Medical management	Usually Appropriate
MR-guided high-frequency focused ultrasound ablation	Usually Appropriate
Uterine artery embolization	Usually Appropriate
Laparoscopic uterine artery occlusion	Usually Not Appropriate
Endometrial ablation	Usually Not Appropriate
Hysterectomy	Usually Not Appropriate

Variant 2. Reproductive age patient with uterine fibroids, symptomatic with heavy uterine bleeding or bulk symptoms (eg, pressure, pain, fullness, bowel, or bladder symptoms), and no desire for future fertility. Initial therapy.

Procedure	Appropriateness Category
Laparoscopic or open myomectomy	Usually Appropriate
Medical management	Usually Appropriate
MR-guided high-frequency focused ultrasound ablation	Usually Appropriate
Uterine artery embolization	Usually Appropriate
Hysterectomy	May Be Appropriate
Hysteroscopic myomectomy	May Be Appropriate
Endometrial ablation	Usually Not Appropriate
Laparoscopic uterine artery occlusion	Usually Not Appropriate

Variant 3. Reproductive age patient with uterine fibroids and concurrent adenomyosis, symptomatic with heavy uterine bleeding or bulk symptoms (eg, pressure, pain, fullness, bladder, or bowel symptoms), and no desire for future fertility. Initial therapy.

Procedure	Appropriateness Category
Medical management	Usually Appropriate
Uterine artery embolization	Usually Appropriate
Hysterectomy	May Be Appropriate
MR-guided high-frequency focused ultrasound ablation	Usually Not Appropriate
Endometrial ablation	Usually Not Appropriate
Hysteroscopic myomectomy	Usually Not Appropriate
Laparoscopic or open myomectomy	Usually Not Appropriate
Laparoscopic uterine artery occlusion	Usually Not Appropriate

Variant 4. Reproductive age patient with pedunculated submucosal uterine fibroids, symptomatic with heavy uterine bleeding. Initial therapy.

Procedure	Appropriateness Category
Hysteroscopic myomectomy	Usually Appropriate
Medical management	Usually Appropriate
Uterine artery embolization	May Be Appropriate
MR-guided high-frequency focused ultrasound ablation	May Be Appropriate
Hysterectomy	Usually Not Appropriate
Endometrial ablation	Usually Not Appropriate
Laparoscopic or open myomectomy	Usually Not Appropriate
Laparoscopic uterine artery occlusion	Usually Not Appropriate

Variant 5. Postmenopausal patient with uterine fibroids, symptomatic with heavy uterine bleeding or bulk symptoms (eg, pressure, pain, fullness, bladder, or bowel symptoms). Negative endometrial biopsy. Next step.

Procedure	Appropriateness Category
Hysterectomy	Usually Appropriate
Laparoscopic or open myomectomy	May Be Appropriate
Uterine artery embolization	May Be Appropriate
Hysteroscopic myomectomy	May Be Appropriate
MR-guided high-frequency focused ultrasound ablation	Usually Not Appropriate
Endometrial ablation	Usually Not Appropriate
Laparoscopic uterine artery occlusion	Usually Not Appropriate
Medical management	Usually Not Appropriate

Variant 6. Reproductive age patient with uterine fibroids desiring pregnancy and experiencing reproductive dysfunction. Initial therapy.

Procedure	Appropriateness Category
Hysteroscopic myomectomy	Usually Appropriate
Laparoscopic or open myomectomy	Usually Appropriate
Uterine artery embolization	May Be Appropriate
Medical management	May Be Appropriate (Disagreement)
MR-guided high-frequency focused ultrasound ablation	May Be Appropriate
Laparoscopic uterine artery occlusion	Usually Not Appropriate
Endometrial ablation	Usually Not Appropriate
Hysterectomy	Usually Not Appropriate

Table 1. Appropriateness category names and definitions

Appropriateness Category Name	Appropriateness Rating	Appropriateness Category Definition
Usually Appropriate	7, 8, or 9	The imaging procedure or treatment is indicated in the specified clinical scenarios at a favorable risk-benefit ratio for patients.
May Be Appropriate	4, 5, or 6	The imaging procedure or treatment may be indicated in the specified clinical scenarios as an alternative to imaging procedures or treatments with a more favorable risk-benefit ratio, or the risk-benefit ratio for patients is equivocal.
May Be Appropriate (Disagreement)	5	The individual ratings are too dispersed from the panel median. The different label provides transparency regarding the panel's recommendation. "May be appropriate" is the rating category and a rating of 5 is assigned.
Usually Not Appropriate	1, 2, or 3	The imaging procedure or treatment is unlikely to be indicated in the specified clinical scenarios, or the risk-benefit ratio for patients is likely to be unfavorable.

SUMMARY OF LITERATURE REVIEW

Introduction/Background

Uterine fibroids, also called leiomyomas or myomas, arise from the smooth muscle cells and fibroblasts of the myometrium and are the most common benign tumor in patients of reproductive age. Fibroid-associated symptoms are greatest leading up to menopause and typically decline in postmenopausal patients. These symptoms include heavy and prolonged uterine bleeding, which can lead to anemia, pelvic pain, bulk symptoms, and reproductive dysfunction. Physical examination, including an abdominal examination, speculum examination, and bimanual pelvic evaluation, are performed to characterize the location, shape, and mobility of the fibroids. Diagnosis is made with pelvic ultrasound (US) or MRI, which further characterizes fibroid location, size, and number. Additional workup may include pregnancy testing, hemoglobin levels, and endometrial biopsy if

features of the patient's presentation raise concern for other causes of heavy menstrual bleeding. See the ACR Appropriateness Criteria® topic on "Fibroids" [1] for further guidance. This document addresses both cisgender females (birth assigned female with woman gender identity) and transgender and gender diverse individuals assigned female at birth.

INITIAL THERAPY DEFINITION

Initial therapy is defined as a first-line treatment option for the medical condition defined by the variant. More than one option can be considered usually appropriate as the initial therapy when:

- There are equivalent alternatives (ie, only one option will be planned to effectively manage the patient's care).

OR

- There are complementary therapies (ie, more than one treatment option is planned to be performed simultaneously or in sequence during the same setting, wherein the therapies provide synergistic or complementary benefits to effectively manage the patient's care).

DISCUSSION OF PROCEDURES BY VARIANT

Variant 1: Reproductive age patient with uterine fibroids, symptomatic with heavy uterine bleeding or bulk symptoms (eg, pressure, pain, fullness, bladder, or bowel symptoms), and a desire to preserve fertility. Initial therapy

Endometrial Ablation. There is no relevant literature regarding the use of endometrial ablation in the treatment of uterine fibroids in patients desiring to preserve fertility. Endometrial ablation is associated with a high risk of pregnancy complications [2].

Hysterectomy. There is no relevant literature regarding the use of hysterectomy in the treatment of uterine fibroids in patients desiring to preserve fertility. Infertility is permanent and irreversible following hysterectomy.

Hysteroscopic Myomectomy. Hysteroscopic myomectomy involves the transvaginal, transcervical placement of a hysteroscope and removal of submucosal uterine fibroids by an electrosurgical wire loop or other instruments and is indicated in patients with submucosal fibroids desiring uterus preservation. Patients with significant intramural or subserosal fibroid burden causing bulk symptoms or heavy menstrual bleeding with concomitant adenomyosis are less likely to experience symptom relief from hysteroscopic myomectomy. Risks include uterine perforation, fluid overload, need for blood transfusion, bowel or bladder injury, endomyometritis, and a need for reintervention [3]. The procedure is associated with shorter hospitalization and a faster return to usual activities compared to laparoscopic or open myomectomy. Improvement in symptom scores and quality of life is equivalent to other surgical approaches at 2 to 3 months [4]. In a randomized trial of myomectomy versus uterine artery embolization (UAE), myomectomy using any approach was shown to have improved quality of life scores at 2 years, although this difference was no longer significant at 4 years [5,6].

Whether hysteroscopic myomectomy improves fertility is a matter of debate, because high-quality evidence on live birth rates following hysteroscopic myomectomy is lacking. Two single-center randomized controlled trials have been performed to date. The first demonstrated no difference in pregnancy rates between patients undergoing hysteroscopic

myomectomy and controls [7]. The second demonstrated improved pregnancy rates after myomectomy; however, data could not be externally validated due to internal inconsistencies in reporting [8,9]. Neither study reported live birth rates. The miscarriage rate was reported in one study and found to be between 30% and 50% [7]. Retrospective studies demonstrate pregnancy rates of 85% after hysteroscopic myomectomy with live birth rates of 65% [10]. Large prospective registries show no significant difference in fertility outcomes among hysteroscopic, laparoscopic, and open myomectomy [11].

Laparoscopic or Open Myomectomy. Laparoscopic or open myomectomy is performed through abdominal incisions and is indicated for subserosal or intramural fibroids. Open myomectomy is preferred over laparoscopic approaches in patients with multiple fibroids or very large uteri. Laparoscopy is associated with shorter hospital stays and a faster return to usual activities compared to open myomectomy [4,12]. Both procedures are associated with an improved quality of life at up to 10 years [13]. Of note, there is increasing utilization of robotic-assisted laparoscopic myomectomy, and outcomes appear similar to traditional laparoscopy in terms of operative time, hospital stay, and postoperative complications.

Large prospective registries show no significant difference in fertility outcomes among hysteroscopic, laparoscopic, and open myomectomy [11]. Of patients trying to conceive, less than half achieve pregnancy after myomectomy at up to 3 years of follow-up. Of these, less than half of these pregnancies will result in a live birth [11]. Case reports have associated laparoscopic and open myomectomy with uterine rupture during subsequent pregnancy [14].

Laparoscopic Uterine Artery Occlusion. Laparoscopic uterine artery occlusion (LUAO) is occasionally used as an adjunct to hysterectomy or myomectomy as a means of decreasing intraoperative blood loss. When performed in isolation for uterine fibroids, it is associated with decrease in heavy menstrual bleeding and fibroid diameter. LUAO was compared to uterine fibroid embolization in a prospective nonrandomized clinical trial, which demonstrated greater reduction in fibroid diameter with UAE (53% versus 39%) and higher frequency of complete infarction with UAE (82% versus 23%). On the other hand, LUAO was associated with decreased postprocedural complications and rehospitalizations. Total pregnancy rates (69% for UAE versus 67% for LUAO), live births (50% versus 46%), and abortion rates (34% versus 33%) were not significantly different between groups [15].

Medical Management. Agents used in the medical management of fibroids include anti-inflammatory medications

(eg, nonsteroidal anti-inflammatory drugs [NSAIDs]) and medications that work by suppressing the reproductive axis to decrease symptoms associated with fibroids such as bleeding and pain. First-line medical management includes estrogen-progestin oral contraceptive pills and progestin-containing intrauterine devices (IUDs), which reduce bleeding symptoms [16]. Tranexamic acid is a nonhormonal alternative agent that may reduce bleeding symptoms in patients with fibroids [17].

Second-line medical management includes parenteral gonadotropin-releasing hormone (GnRH) agonists (eg, leuprolide acetate) and oral GnRH antagonists (eg, elagolix, linzagolix, and relugolix) [18-23]. In addition to reducing bleeding symptoms, both GnRH agonists and antagonists are effective at significantly reducing tumor volume and are commonly used for short courses to decrease fibroid size in preparation for surgery [24]. As monotherapy, both GnRH agonists and antagonists are associated with hypoestrogenic effects including headaches, hot flashes, hypertension, and loss of bone mineral density. Combination treatment with low doses of estrogen and progestin mitigates these symptoms and is an FDA-approved treatment option for fibroid-related heavy menstrual bleeding [19,25]. Although these agents are often chosen by patients interested in uterus-preserving therapy or preservation of future fertility, fertility is suppressed during treatment and cessation of therapy leads to rapid recurrence of symptoms.

There are growing data supporting the efficacy of progesterone receptor modulators such as ulipristal acetate. These agents reduce both bleeding and bulk symptoms and can be administered intermittently, allowing for menstruation during medication breaks [26,27]. Efficacy of continuous use after 3 months and intermittent use for 2 years with comparison to both placebo and GnRH agonists has been demonstrated in randomized controlled trials [28-30]. However, reports of hepatotoxicity are a barrier to its approval for use in the United States [31,32].

MR-Guided High-Frequency Focused Ultrasound Ablation. MR-guided focused US surgery (MRgFUS) uses high-intensity US waves to target and thermally ablate uterine fibroids, resulting in coagulative necrosis without damage to intervening tissues. Complications are rare and include skin burns, nerve damage, vaginal discharge, bowel injury, deep vein thrombosis, and abdominal wall pain and swelling [33].

A recent randomized controlled trial compared MRgFUS to placebo and demonstrated significantly greater improvement in quality of life, significantly greater decrease in fibroid diameter (−18% versus no change), and a reintervention rate of 33% at 2 years [34].

The randomized controlled Fibroid Interventions: Reducing Symptoms Today and Tomorrow (FIRSTT) trial compared UAE to MRgFUS and demonstrated that MRgFUS was associated with a higher reintervention rate (30% versus 13%) and decreased symptom control compared to UAE [35]. Reinterventions included hysterectomy, myomectomy, or UAE. Uterine Fibroid Symptom and Quality of Life (UFS-QOL) improved in both groups, with UAE demonstrating a significantly greater improvement in scores at all time points (6-, 12-, and 24-months). Compared to UAE, MRgFUS is also longer (6.75 hours versus 2.3 hours) and is occasionally performed over 2 days. MRgFUS is associated with decreased postprocedural pain and narcotic and anti-inflammatory use as well as a faster recovery. Frequency and severity of adverse events is similar for both procedures, with a low rate of major adverse events for both [36]. Compared to myomectomy or hysterectomy, a recent large prospective trial demonstrated a major adverse event rate of 0.2% for focused US and 12.6% for surgical approaches. In this study, MRgFUS also demonstrated a greater improvement in symptoms and quality of life scores compared to baseline at 6 and 12 months [37].

Reintervention rates similar to UAE have been reported. One study reported a reintervention rate of 4% at 1 year, 13% at 2 years, 19% at 3 years, and 23% at 4 years [38], although other studies have reported reintervention rates as high as 30% at 2 years [39]. In cohort studies, quality of life and rates of reintervention are similar between patients undergoing laparoscopic myomectomy and MRgFUS at 5 years [40].

No randomized controlled trials assessing fertility have been performed for MRgFUS. The best evidence comes from a prospective cohort of 51 women who underwent MRgFUS. Among these women, 54 pregnancies were recorded with a mean time of conception 8 months after treatment. Live births were achieved in 41%. There was a 28% spontaneous abortion rate, an 11% rate of elective termination, and a 20% rate of ongoing pregnancy beyond 20 weeks at follow-up [41]. The FIRSTT trial reported anti-Mullerian hormone levels, a surrogate marker of ovarian reserve, in UAE versus MRgFUS, and found that both procedures decreased anti-Mullerian hormone, with UAE decreasing anti-Mullerian hormone significantly more at 1 year [35].

Uterine Artery Embolization. UAE is a technique using a transfemoral or transradial arterial approach to introduce a catheter into the uterine arteries. Embolic materials (eg, gelatin, microspheres, or coils) introduced through the catheter cause arterial occlusion, ischemic necrosis, and involution of fibroids. Indications for UAE include bulk

symptoms and heavy menstrual bleeding. Side effects of UAE include pelvic pain, vaginal expulsion of submucosal fibroids, and postembolization syndrome, a flu-like syndrome that presents with pain, nausea, fevers, and leukocytosis. Since the first published study in 1995, UAE has been shown to cause persistent decreases in pain, heavy menstrual bleeding, and an average decrease in uterine fibroid size of >50% at 5 years [42]. Randomized controlled trials have demonstrated that compared to myomectomy, UAE is equally effective at reducing heavy menstrual bleeding at 4 years [5]. Further, UAE is associated with a decreased risk of blood transfusion and shorter hospital stays, and rates of new fibroid formation are significantly lower with UAE than with myomectomy [42]. Quality of life scores and reintervention rate at 4 years are not significantly different between myomectomy and UAE [5]. Ten-year follow-up from the Embolization vs Hysterectomy (EMMY) trial, which did not permit repeat embolization after initial treatment, reported secondary hysterectomy rates of 28% at 5 years and 35% at 10 years [13].

In a meta-analysis comparing UAE and MRgFUS, UAE has been associated with improved symptom relief, improved quality of life, lower reintervention rates, and lower pregnancy rates [43].

Historically, fertility after UAE has been a topic of debate, but a growing number of studies demonstrated high rates of live birth following UAE in patients trying to conceive. Recent prospective studies demonstrate high live birth rates (10/12 pregnancies, 1 ongoing pregnancy) with low miscarriage rates (1/12) [44]. The randomized FEMME (Treating Fibroids with Either Embolisation or Myomectomy to Measure the Effect on Quality of Life Among Women Wishing to Avoid Hysterectomy) trial found no significant difference in levels of biomarkers of ovarian reserve between UAE and myomectomy [6]. At 4-year follow-up, pregnancy and birth rates were too low for statistical analysis but demonstrated that a majority of pregnancies in UAE resulted in live births (9/15). The miscarriage rate was 33% (5/15) [5]. A retrospective cohort study of reproductive outcomes for women who underwent UAE for fibroids, adenomyosis, or both demonstrated a live birth rate of 73% (109/148) with a miscarriage rate of 17.5% (26/148) [45]. These findings are consistent with another retrospective study reporting a spontaneous pregnancy rate of 29.5% and 40.1% following UAE at 1 and 2 years, respectively, with a live birth rate of 81% (148 live births following 182 pregnancies) [46].

Despite these findings, the question of fertility after UAE is haunted by an early randomized controlled trial, which demonstrated a higher miscarriage rate after UAE (9/15) compared with myomectomy (6/33) [47]. This study

should be interpreted with caution because it excluded patients with submucosal fibroids from the myomectomy arm, represented midterm results with a short follow-up time, and had a low number of women attempting conception in the UAE arm compared to myomectomy. Further, the high rate of miscarriage was inconsistent with data reported from prospective trials at the time. In light of these shortcomings, and newer evidence to date which contradicts these findings, there is promising evidence that UAE is comparable to myomectomy with regards to fertility, and future trials are needed.

Variant 2: Reproductive age patient with uterine fibroids, symptomatic with abnormally heavy uterine bleeding or bulk symptoms (eg, pressure, pain, fullness, bowel, or bladder symptoms), and no desire for future fertility. Initial therapy

Endometrial Ablation. Endometrial ablation is a minimally invasive technique that can be performed for patients with uterine fibroids associated with heavy menstrual bleeding who are refractory or intolerant to medical therapy. This technique uses thermal energy to irreversibly destroy the uterine lining and is only indicated in patients who do not desire future pregnancy. In a small randomized controlled trial of hysterectomy versus thermal balloon ablation, ablation was associated with amenorrhea or hypomenorrhea in all patients for up to 2 years [48]. However, endometrial ablation is not a form of contraception, and large population-based linkage studies demonstrate an elevated risk of extrauterine pregnancy, preterm delivery, and stillbirth with this procedure [49]. Given these risks, endometrial ablation should only be performed after failure of medical therapy.

Hysterectomy. Hysterectomy, whether transvaginal, laparoscopic, or abdominal, remains the most common treatment for uterine fibroids, accounting for three-quarters of fibroid treatment in the United States [50], and provides definitive resolution of all fibroid-related symptoms for patients who do not desire future pregnancy. Hysterectomy eliminates the risk of new fibroid formation and allows for simultaneous treatment of concomitant intrauterine disease such as adenomyosis, endometriosis, high-risk cervical dysplasia, uterine prolapse, or intrauterine malignancy. If there is not another indication for removal, the ovaries are left in place to avoid precipitating menopause and associated cardiovascular risks. Even with bilateral ovarian conservation, hysterectomy alone is associated with elevated risk of subsequent cardiovascular disease and mood disorders. Some studies report increased mortality, especially when performed at a young age [51-53]. Short-term complications

may include abscess, venous thromboembolism, damage to ureter, bowel, or bladder, bleeding requiring transfusion, and vaginal cuff complications. Randomized studies have demonstrated increased rate of severe complications, longer hospitalization, and a longer return to regular activities with hysterectomy compared to UAE despite similar symptom relief [54], suggesting that hysterectomy should be avoided if a less invasive procedure is available. Cohort studies and registries have reported long-term effects of hysterectomy, including increased risk of cardiovascular disease [51], osteoporosis and bone fracture [55], and dementia [56]. Thus, unless there are other reasons for hysterectomy, an alternative to hysterectomy should be first-line treatment.

If hysterectomy is indicated, the least invasive route for hysterectomy should be performed. Abdominal hysterectomy is associated with longer hospital stay, recovery time, and greater pain and risk of infection compared to other approaches. Vaginal hysterectomy is associated with shorter operating times, a faster return to normal activities, and a better quality of life compared to abdominal hysterectomy. Laparoscopic hysterectomy is associated with a faster return to normal activities, shorter hospital stays, and lower rates of wound infection compared to abdominal hysterectomy [57]. Of note, there is increasing utilization of robotic-assisted hysterectomy, and outcomes appear similar to traditional laparoscopy in terms of operative time, hospital stay, and postoperative complications [58].

Hysteroscopic Myomectomy. Hysteroscopic myomectomy involves the transvaginal, transcervical placement of a hysteroscope and removal of submucosal uterine fibroids by an electrosurgical wire loop and other instruments and is indicated in patients with submucosal fibroids desiring uterus preservation. Patients with significant intramural or subserosal fibroid burden causing bulk symptoms or heavy menstrual bleeding with concomitant adenomyosis are less likely to experience symptom relief from hysteroscopic myomectomy. Risks include uterine perforation, fluid overload, the need for blood transfusion, bowel or bladder injury, endomyometritis, and the need for reintervention [3]. The procedure is associated with shorter hospitalization and a faster return to usual activities compared to laparoscopic or open myomectomy. Improvement in symptom scores and quality of life is equivalent to other surgical approaches at 2 to 3 months [4]. In a randomized trial of myomectomy versus UAE, myomectomy using any approach was shown to have improved quality of life scores at 2 years, although this difference was no longer significant at 4 years [5].

Patients with no desire for future fertility should be counseled that pregnancy is possible after hysteroscopic myomectomy.

Laparoscopic or Open Myomectomy. Laparoscopic or open myomectomy is performed through abdominal incisions and is indicated for subserosal or intramural fibroids. Open myomectomy is preferred over laparoscopic approaches in patients with multiple fibroids or very large uteri. Laparoscopy is associated with shorter hospital stays and a faster return to usual activities compared to open myomectomy [4,12]. Both procedures are associated with an improved quality of life at up to 10 years [13]. Of note, there is increasing utilization of robotic-assisted laparoscopic myomectomy, and outcomes appear similar to traditional laparoscopy in terms of operative time, hospital stay, and postoperative complications.

Patients with no desire for future fertility should be counseled that pregnancy is possible after laparoscopic or open myomectomy.

Laparoscopic Uterine Artery Occlusion. LUAO is commonly used as an adjunct to hysterectomy or myomectomy as a means of decreasing intraoperative blood loss. When performed in isolation for uterine fibroids, it is associated with decreased heavy menstrual bleeding and fibroid diameter. LUAO was compared to uterine fibroid embolization in a prospective nonrandomized clinical trial, which demonstrated greater reduction in fibroid diameter with UAE (53% versus 39%) and higher frequency of complete infarction with UAE (82% versus 23%). On the other hand, LUAO was associated with decreased post-procedural complications and rehospitalizations. Total pregnancy rates (69% for UAE versus 67% for LUAO), live births (50% versus 46%), and abortion rates (34% versus 33%) were not significantly different between groups [15].

Patients with no desire for future fertility should be counseled that pregnancy is possible after LUAO.

Medical Management. Agents used in the medical management of fibroids include anti-inflammatory medications (eg, NSAIDs) and medications that work by suppressing the reproductive axis to decrease symptoms associated with fibroids such as bleeding and pain. First-line medical management includes estrogen-progestin oral contraceptive pills and progestin-containing IUDs, which reduce bleeding symptoms [16]. Tranexamic acid is a nonhormonal alternative agent that may reduce bleeding symptoms in patients with fibroids [17].

Second line medical management includes parenteral GnRH agonists (eg, leuprolide acetate) and oral GnRH antagonists (eg, elagolix, linzagolix, and relugolix) [18-23]. In addition to reducing bleeding symptoms, both GnRH agonists and antagonists are effective at significantly reducing tumor volume and are commonly used for short courses to decrease fibroid size in preparation for surgery [24]. As monotherapy, both GnRH agonists and antagonists are

associated with hypoestrogenic effects including headaches, hot flashes, hypertension, and loss of bone mineral density. Combination treatment with low doses of estrogen and progestin mitigates these symptoms and is an FDA-approved treatment option for fibroid-related heavy menstrual bleeding [19,25]. Although these agents are often chosen by women interested in uterus-preserving therapy or preservation of future fertility, fertility is suppressed during treatment and cessation of therapy leads to rapid recurrence of symptoms.

There is growing data supporting the efficacy of progesterone receptor modulators such as ulipristal acetate. These agents reduce both bleeding and bulk symptoms and can be administered intermittently, allowing for menstruation during medication breaks [26,27]. Efficacy of continuous use after 3 months and intermittent use for 2 years with comparison to both placebo and GnRH agonists has been demonstrated in randomized controlled trials [28-30]. However, reports of hepatotoxicity are a barrier to its approval for use in the United States [31,32].

MR-Guided High-Frequency Focused Ultrasound Ablation. MRgFUS uses high-intensity US waves to target and thermally ablate uterine fibroids, resulting in coagulative necrosis without damage to intervening tissues. Complications are rare and include skin burns, nerve damage, vaginal discharge, bowel injury, deep vein thrombosis, and abdominal wall pain and swelling [33].

A recent randomized controlled trial compared MRgFUS to placebo and demonstrated significantly greater improvement in quality of life, significantly greater decrease in fibroid diameter (−18% versus no change), and a reintervention rate of 33% at 2 years [34].

The randomized controlled FIRSST trial compared UAE to MRgFUS and demonstrated that MRgFUS was associated with a higher reintervention rate (30% versus 13%) and decreased symptom control compared to UAE [35]. Reinterventions included hysterectomy, myomectomy, or UAE. UFS-QOL improved in both groups, with UAE demonstrating a significantly greater improvement in scores at all time points (6-, 12-, and 24-months). Compared to UAE, MRgFUS is also longer (6.75 hours versus 2.3 hours) and is occasionally performed over 2 days. MRgFUS is associated with decreased postprocedural pain and narcotic and anti-inflammatory use as well as faster recovery. Frequency and severity of adverse events is similar for both procedures, with a low rate of major adverse events for both [36]. Compared to myomectomy or hysterectomy, a recent large prospective trial demonstrated a major adverse event rate of 0.2% for focused US and 12.6% for surgical approaches. In this study, MRgFUS also demonstrated a greater improvement in symptoms and quality of life scores compared to baseline at 6 and 12 months [37].

Reintervention rates similar to UAE have been reported. One study reported a reintervention rate of 4% at 1 year, 13% at 2 years, 19% at 3 years, and 23% at 4 years [38], although other studies have reported reintervention rates as high as 30% at 2 years [39]. In cohort studies, quality of life and rates of reintervention are similar between patients undergoing laparoscopic myomectomy and MRgFUS at 5 years [40].

Patients with no desire for future fertility should be counseled that pregnancy is possible after MRgFUS.

Uterine Artery Embolization. UAE is a technique using a transfemoral or transradial arterial approach to introduce a catheter into the uterine arteries. Embolic material (eg, gelatin, microspheres, or coils) introduced through the catheter cause arterial occlusion, ischemic necrosis, and involution of fibroids. Indications for UAE include bulk symptoms and heavy menstrual bleeding. Side effects of UAE include pelvic pain, vaginal expulsion of submucosal fibroids, and post-embolization syndrome, a flu-like syndrome that presents with pain, nausea, fevers, and leukocytosis. Since the first published study in 1995, UAE has been shown to cause persistent decreases in pain, heavy menstrual bleeding, and an average decrease in uterine fibroid size of >50% at 5 years [42]. Randomized controlled trials have demonstrated that compared to myomectomy, UAE is equally effective at reducing heavy menstrual bleeding at 4 years [5]. Further, UAE is associated with a decreased risk of blood transfusion and shorter hospital stays, and rates of new fibroid formation are significantly lower with UAE than with myomectomy [42]. Quality of life scores and reintervention rate at 4 years are not significantly different between myomectomy and UAE [5]. Ten year follow-up from the EMMY trial, which did not permit repeat embolization after initial treatment, reported secondary hysterectomy rates of 28% at 5 years and 35% at 10 years [13].

In a meta-analysis comparing UAE and MRgFUS, UAE has been associated with improved symptom relief, improved quality of life, lower reintervention rates, and lower pregnancy rates [43].

Patients with no desire for future fertility should be counseled that pregnancy is possible after UAE.

Variant 3: Reproductive age patient with uterine fibroids and concurrent adenomyosis, symptomatic with heavy uterine bleeding or bulk symptoms (eg, pressure, pain, fullness, bladder, or bowel symptoms), and no desire for future fertility. Initial therapy

Endometrial Ablation. There is no relevant literature regarding the use of endometrial ablation in the treatment of

uterine fibroids in patients with concomitant adenomyosis. Treatment failure of endometrial ablation for heavy menstrual bleeding has been associated with the presence of adenomyosis [59].

Hysterectomy. Hysterectomy, whether transvaginal, laparoscopic, or abdominal, remains the most common treatment for uterine fibroids, accounting for three-quarters of fibroid treatment in the United States [50], and provides definitive resolution of all fibroid-related symptoms for patients who do not desire future pregnancy. Hysterectomy eliminates the risk of new fibroid formation and allows for simultaneous treatment of concomitant intrauterine disease such as adenomyosis, endometriosis, high risk cervical dysplasia, uterine prolapse, or intrauterine malignancy. If there is not another indication for removal, the ovaries are left in place to avoid precipitating menopause and associated cardiovascular risks. Even with bilateral ovarian conservation, hysterectomy alone is associated with elevated risk of subsequent cardiovascular disease and mood disorders. Some studies report increased mortality, especially when performed at a young age [51-53]. Short-term complications include abscess, venous thromboembolism, damage to ureter, bowel, or bladder, bleeding requiring transfusion, and vaginal cuff complications. Randomized studies have demonstrated increased rate of severe complications, longer hospitalization, and longer return to regular activities with hysterectomy compared to UAE despite similar symptom relief [54], suggesting that hysterectomy should be avoided if a less invasive procedure is available. Cohort studies and registries have reported long-term effects of hysterectomy including increased risk of cardiovascular disease [51], osteoporosis and bone fracture [55], and dementia [56].

If hysterectomy is indicated, the least invasive route for hysterectomy should be performed. Abdominal hysterectomy is associated with longer hospital stay, recovery time, and greater pain and risk of infection compared to other approaches. Vaginal hysterectomy is associated with shorter operating times, faster return to normal activities and better quality of life compared to abdominal hysterectomy. Laparoscopic hysterectomy is associated with a faster return to normal activities, shorter hospital stays, and lower rates of wound infection compared to abdominal hysterectomy [57]. Of note, there is increasing utilization of robotic-assisted hysterectomy and outcomes appear similar to traditional laparoscopy in terms of operative time, hospital stay, and postoperative complications [58].

Hysteroscopic Myomectomy. There is no relevant literature regarding the use of myomectomy alone in the treatment of uterine fibroids in patients with concurrent adenomyosis. Adenomyosis is unlikely to be effectively addressed with this technique.

Laparoscopic or Open Myomectomy. There is no relevant literature regarding the use of myomectomy alone in the treatment of uterine fibroids in patients with concurrent adenomyosis. Adenomyosis is unlikely to be effectively addressed with this technique.

Laparoscopic Uterine Artery Occlusion. There is no relevant literature regarding the use of LUAO alone in the treatment of uterine fibroids in patients with concurrent adenomyosis.

Medical Management. Although studies specifically exploring the question of heavy menstrual bleeding in patients with fibroids and concurrent adenomyosis are lacking, progestin IUDs and combined oral contraceptives have both been shown to reduce painful and heavy menstrual bleeding in randomized controlled trials [60-62]. Progestin IUDs are clinically favored due to local mechanism of action, lower levels of systemic hormones, long duration of action after placement, and user independence. A recent randomized controlled trial demonstrated significant improvement in pain and bleeding in women with adenomyosis treated with progestin IUD versus combined oral contraceptives [63]. Additionally, pooled analysis of 2 randomized controlled trials demonstrated that the presence of concomitant adenomyosis does not decrease the effectiveness of oral GnRH antagonist combinations in the treatment of heavy menstrual bleeding [64]. These therapies will not treat associated bulk symptoms.

MR-Guided High-Frequency Focused Ultrasound Ablation. There is no relevant literature regarding the use of MRgFUS ablation in the treatment of uterine fibroids in patients with concurrent adenomyosis.

Uterine Artery Embolization. Evidence from prospective cohort studies supports the use of UAE for patients with adenomyosis and fibroids who fail conservative measures and desire uterus-preserving therapy. Prospective cohort studies of women with adenomyosis and fibroids demonstrate improvement in quality of life and symptom scores, especially when fibroids predominate [65]. In patients with adenomyosis with or without fibroids, UAE improved symptom scores and quality of life at up to 7 years follow-up. Eighteen percent of patients underwent hysterectomy for persistent symptoms [66,67]. A recent meta-analysis reported short-term (<12 months) and long-term (>12 months) improvement in symptoms in 94% and 85%, respectively, with a 7% rate of hysterectomy for persistent symptoms [68]. Successful pregnancy has been reported after UAE for adenomyosis with fibroids symptoms [68]; however, comprehensive data on fertility and pregnancy is lacking, and patients should be counseled accordingly.

The results of the ongoing multicenter nonblinded randomized controlled QUESTA trial (Quality of Life after Embolization versus Hysterectomy in Adenomyosis) aims to provide a comparison of UAE and hysterectomy outcomes in patients with adenomyosis [69].

Variant 4: Reproductive age patient with pedunculated submucosal uterine fibroids, symptomatic with heavy uterine bleeding. Initial therapy

Endometrial Ablation. There is no relevant literature regarding the use of endometrial ablation as the initial treatment of pedunculated submucosal uterine fibroids.

Hysterectomy. Hysterectomy, whether transvaginal, laparoscopic, or abdominal, remains the most common treatment for uterine fibroids, accounting for three-quarters of fibroid treatment in the United States [50], and provides definitive resolution of all fibroid-related symptoms for patients symptomatic with heavy uterine bleeding. However, there is no relevant literature regarding the use of hysterectomy as the initial treatment of pedunculated submucosal uterine fibroids as less invasive and equally effective approaches are available.

Hysteroscopic Myomectomy. Hysteroscopic myomectomy is the procedure of choice for pedunculated submucosal uterine fibroids <5 cm. The procedure is associated with shorter hospitalization and faster return to usual activities compared to laparoscopic or open myomectomy. Data from large registries demonstrate that improvement in symptom scores and quality of life is equivalent to more invasive surgical approaches at 2 to 3 months [4].

Laparoscopic or Open Myomectomy. There is no relevant literature regarding the use of laparoscopic or open myomectomy in the treatment of pedunculated submucosal uterine fibroids.

Laparoscopic Uterine Artery Occlusion. There is no relevant literature regarding the use of LUAO in the treatment of pedunculated submucosal uterine fibroids.

Medical Management. Some forms of medical management can be considered for patients with pedunculated submucosal uterine fibroids associated with heavy bleeding. First-line medical management includes NSAIDs and estrogen-progestin oral contraceptive pills, which reduce bleeding symptoms [16]. Tranexamic acid is a nonhormonal alternative agent that may reduce bleeding symptoms in patients with fibroids [17].

Second line medical management includes parenteral GnRH agonists (eg, leuprolide acetate) and oral GnRH antagonists (eg, elagolix, linzagolix, and relugolix) [18-23]. In addition to reducing bleeding symptoms, both GnRH

agonists and antagonists are effective at significantly reducing tumor volume and are commonly used for short courses to decrease fibroid size in preparation for surgery [24]. As monotherapy, both GnRH agonists and antagonists are associated with hypoestrogenic effects including headaches, hot flashes, hypertension, and loss of bone mineral density. Combination treatment with low doses of estrogen and progestin mitigates these symptoms and is an FDA-approved treatment option for fibroid-related heavy menstrual bleeding [19,25]. Although these agents are often chosen by patients interested in uterus-preserving therapy or preservation of future fertility, fertility is suppressed during treatment and cessation of therapy leads to rapid recurrence of symptoms.

There is growing data supporting the efficacy of progesterone receptor modulators such as ulipristal acetate. These agents reduce both bleeding and bulk symptoms and can be administered intermittently, allowing for menstruation during medication breaks [26,27]. Efficacy of continuous use after 3 months and intermittent use for 2 years with comparison to both placebo and GnRH agonists has been demonstrated in randomized controlled trials [28-30]. However, reports of hepatotoxicity are a barrier to its approval for use in the United States [31,32].

MR-Guided High-Frequency Focused Ultrasound Ablation. Evidence for MRgFUS for pedunculated submucosal fibroids is limited and derives from case reports and small prospective studies [70]. One prospective study demonstrated a 66% decrease in volume of perfused fibroid with a corresponding 30% decrease in diameter of pedunculated submucosal fibroids at 6 months. Treatment was associated with a significant improvement in symptom score, with 89% of women reporting an improvement in bulk symptoms [71]. These findings are consistent with prior data on pedunculated submucosal fibroids treated with UAE [72].

Uterine Artery Embolization. The literature on therapeutic outcomes of patients undergoing UAE for fibroids does not distinguish patients with pedunculated submucosal fibroids. Patients undergoing UAE for submucosal fibroids can experience fibroid expulsion. One retrospective study demonstrated a 50% rate of complete expulsion, with low complication rates [73].

Variant 5: Postmenopausal patient with uterine fibroids, symptomatic with heavy uterine bleeding or bulk symptoms (eg, pressure, pain, fullness, bladder, or bowel symptoms). Negative endometrial biopsy. Next step

With rare exception, the natural history of fibroids is shrinkage and symptom resolution with menopause due to

decreased circulating estrogen and the cessation of menses. Given this natural history and the elevated incidence of cancer in this group, suspicion for malignancy should be increased in postmenopausal patients with fibroids and persistent abnormal uterine bleeding, fibroid growth, or both. It is essential to pursue endometrial biopsy prior to intervention because it can rule out endometrial neoplasia and, in some cases, diagnose sarcoma. There is no evidence in favor of any one approach for symptomatic uterine fibroids in postmenopausal patients with a negative endometrial biopsy.

Endometrial Ablation. There is no relevant literature regarding the use of endometrial ablation in the treatment of postmenopausal patients with fibroids and negative endometrial biopsy.

Hysterectomy. Hysterectomy may be helpful in postmenopausal patients with symptomatic fibroids and a negative endometrial biopsy. In this setting, benefits of hysterectomy include the ability for pathologic evaluation of the uterus to confirm absence of malignancy. Additionally, postmenopausal patients are less likely to pursue fertility sparing treatments. These considerations must be weighed against the potential for increased surgical risk in this older cohort of patients.

Hysterectomy, whether transvaginal, laparoscopic, or abdominal, remains the most common treatment for uterine fibroids, accounting for three-quarters of fibroid treatment in the United States [50], and provides definitive resolution of all fibroid-related symptoms for patients who do not desire future pregnancy. Hysterectomy eliminates the risk of new fibroid formation and allows for simultaneous treatment of concomitant intrauterine disease such as adenomyosis, intrauterine endometriosis, or intrauterine malignancy. Short-term complications include abscess, venous thromboembolism, damage to ureter, bowel, or bladder, bleeding requiring transfusion, and vaginal cuff complications. Randomized studies have demonstrated increased rate of severe complications, longer hospitalization, and a longer return to regular activities with hysterectomy compared to UAE despite similar symptom relief [54], suggesting that hysterectomy should be avoided if a less invasive procedure is available. Cohort studies and registries have reported long-term effects of hysterectomy, including increased risk of cardiovascular disease [51], osteoporosis and bone fracture [55], and dementia [56].

If hysterectomy is indicated, the least invasive route for hysterectomy should be performed. Abdominal hysterectomy is associated with longer hospital stay, recovery time, and greater pain and risk of infection compared to other approaches. Vaginal hysterectomy is associated with shorter operating times, a faster return to normal activities, and a

better quality of life compared to abdominal hysterectomy. Laparoscopic hysterectomy is associated with a faster return to normal activities, shorter hospital stays, and lower rates of wound infection compared to abdominal hysterectomy [57].

Hysteroscopic Myomectomy. Hysteroscopic myomectomy may be helpful in postmenopausal patients with symptomatic fibroids and negative endometrial biopsy when fibroids are submucosal and associated with postmenopausal bleeding. Hysteroscopic myomectomy involves the transvaginal, transcervical placement of a hysteroscope and removal of submucosal uterine fibroids by an electrosurgical wire loop or other instruments and is indicated in patients with submucosal fibroids. Risks include uterine perforation, fluid overload, a need for blood transfusion, bowel or bladder injury, endomyometritis, and a need for reintervention [3]. The procedure is associated with shorter hospitalization and a faster return to usual activities compared to laparoscopic or open myomectomy. Improvement in symptom scores and quality of life is equivalent to other surgical approaches at 2 to 3 months [4]. In a randomized trial of myomectomy versus UAE, myomectomy using any approach was shown to have improved quality of life scores at 2 years, although this difference was no longer significant at 4 years [5]. There is no additional relevant literature regarding the use of hysteroscopic myomectomy specific to the treatment of postmenopausal patients with fibroids and negative endometrial biopsy.

Laparoscopic or Open Myomectomy. Laparoscopic or open myomectomy may be helpful in postmenopausal patients with fibroids causing bulk symptoms and negative endometrial biopsy. There is no additional relevant literature regarding the use of laparoscopic or open myomectomy specific to the treatment of postmenopausal patients with fibroids and negative endometrial biopsy.

Laparoscopic Uterine Artery Occlusion. There is no relevant literature regarding the use of LUAO in the treatment of postmenopausal patients with fibroids and negative endometrial biopsy.

Medical Management. There is no relevant literature regarding the use of medical management in the treatment of postmenopausal patients with fibroids and negative endometrial biopsy.

MR-Guided High-Frequency Focused Ultrasound Ablation. There is no relevant literature regarding the use of MRgFUS ablation in the treatment of postmenopausal patients with fibroids and negative endometrial biopsy.

Uterine Artery Embolization. In postmenopausal patients with abnormal uterine bleeding, even in the presence

of fibroids, uterine sarcoma and endometrial cancer must be ruled out as the underlying cause prior to treatment with minimally invasive therapy. Evidence from a small retrospective study supports UAE as a safe and effective procedure for the treatment of fibroids in postmenopausal patients. Complete fibroid necrosis was seen in all patients with accompanying symptom resolution (urinary frequency and vaginal bleeding) in 89% [74]. Given the increased risk of uterine malignancy in this population, all postmenopausal patients with abnormal uterine bleeding should undergo workup to rule out endometrial cancer prior to proceeding with UAE.

In addition to endometrial cancer, there is a risk that presumed fibroids actually represent uterine sarcoma. Retrospective studies estimate the risk of unexpected uterine sarcoma following surgery for presumed fibroids at 2.94 per 1,000. However, stratification by age reveals lower risk in patients <30 years of age and a higher risk in older patients (up to 10.1 per 1,000 in patients 75-79 years of age) [75]. Fibroids and uterine sarcoma can present similarly, and although MRI is a useful tool to distinguish the two, there is no way to definitively diagnose them prior to surgery. As a result, continued fibroid growth or bleeding after menopause should raise suspicion for uterine sarcoma [76].

Variant 6: Reproductive age patient with uterine fibroids desiring pregnancy and experiencing reproductive dysfunction. Initial therapy

Endometrial Ablation. There is no relevant literature regarding the use of endometrial ablation in the treatment of fibroids in patients desiring pregnancy and experiencing reproductive dysfunction. Endometrial ablation is associated with a high risk of pregnancy complications [2].

Hysterectomy. There is no relevant literature regarding the use of hysterectomy in the treatment of fibroids in patients desiring pregnancy and experiencing reproductive dysfunction. Infertility is permanent and irreversible following hysterectomy.

Hysteroscopic Myomectomy. If a complete infertility workup fails to identify another source of infertility, hysteroscopic myomectomy may be offered to patients with fibroids who desire pregnancy and are experiencing reproductive dysfunction. However, whether hysteroscopic myomectomy improves fertility is a matter of debate, and high-quality evidence on live birth rates following hysteroscopic myomectomy is lacking. Two single-center randomized controlled trials have been performed to date. The first demonstrated no difference in pregnancy rates between patients undergoing hysteroscopic myomectomy and

controls [7]. The second demonstrated improved pregnancy rates after myomectomy; however, data could not be externally validated due to internal inconsistencies in reporting [8,9]. Neither study reported live birth rates. The miscarriage rate was reported in one study and found to be between 30% and 50% [7]. Retrospective studies demonstrate pregnancy rates of 85% after hysteroscopic myomectomy with live birth rates of 65% [10]. Large prospective registries show no significant difference in fertility outcomes among hysteroscopic, laparoscopic, and open myomectomy [11].

Laparoscopic or Open Myomectomy. Evidence for laparoscopic or open myomectomy in patients with fibroids and otherwise unexplained infertility comes from two historic randomized controlled trials. Both demonstrated similar pregnancy and live birth rates between patients with infertility and at least 1 fibroid >5 cm undergoing laparoscopic versus open myomectomy [77,78]. The combined miscarriage rate was comparable to the general population at 14% and was not significantly different between groups. Laparoscopic myomectomy was associated with decreased postoperative fever, shorter hospital stays, and a smaller decrease in postoperative hemoglobin [78].

Laparoscopic Uterine Artery Occlusion. There is no relevant literature regarding the use of LUAO in the treatment of fibroids in patients desiring pregnancy and experiencing reproductive dysfunction.

Medical Management. Although most accepted medical therapies suppress fertility, a recent study of ulipristal acetate in patients with infertility and submucosal fibroids undergoing in vitro fertilization demonstrated a 41% reduction in fibroid volume and a pregnancy rate similar to matched controls without fibroids [79].

MR-Guided High-Frequency Focused Ultrasound Ablation. Evidence for MRgFUS for fertility enhancement in patients with fibroids and reproductive dysfunction is limited to case reports [80,81]. A randomized controlled trial to investigate the efficacy and safety of MRgFUS for this indication was terminated due to lack of enrollment [82].

Uterine Artery Embolization. Pisco et al [46] retrospectively studied a population of patients with infertility and fibroids or adenomyosis who underwent UAE. Patients included in the study had failed to conceive for at least 1 year, and some had previously undergone myomectomy or attempted in vitro fertilization. The spontaneous pregnancy rate at 1 and 2 years following UAE was 29.5% and 40.1%, respectively, with a live birth rate of 81% (148 live births following

182 pregnancies). The authors did not find a statistically significant difference in pregnancy outcome between partial UAE and conventional UAE.

SUMMARY OF RECOMMENDATIONS

- **Variant 1:** Laparoscopic or open myomectomy, medical management, MRgFUS, or UAE is usually appropriate for the initial therapy of a reproductive age patient with uterine fibroids, symptomatic with heavy uterine bleeding or bulk symptoms (eg, pressure, pain, fullness, bladder, or bowel symptoms), and a desire to preserve fertility. In most cases, medical management should be trialed prior to pursuing more invasive therapies. The procedures are equivalent alternatives (ie, only one procedure will be ordered to provide the clinical information to effectively manage the patient's care).
- **Variant 2:** Laparoscopic or open myomectomy, medical management, MRgFUS, or UAE is usually appropriate for the initial therapy for a reproductive age patient with uterine fibroids, symptomatic with heavy uterine bleeding or bulk symptoms (eg, pressure, pain, fullness, bowel, or bladder symptoms), and no desire for future fertility. In most cases, medical management should be trialed prior to pursuing more invasive therapies. The procedures are equivalent alternatives (ie, only one procedure will be ordered to provide the clinical information to effectively manage the patient's care).
- **Variant 3:** Medical management or UAE is usually appropriate for the initial therapy for a reproductive age patient with uterine fibroids and concurrent adenomyosis, symptomatic with heavy uterine bleeding or bulk symptoms (eg, pressure, pain, fullness, bladder, or bowel symptoms), and no desire for future fertility. In most cases, medical management should be trialed prior to pursuing more invasive therapies.
- **Variant 4:** Hysteroscopic myomectomy or medical management is usually appropriate for the initial therapy for a reproductive age patient with pedunculated submucosal uterine fibroids that is symptomatic with heavy uterine bleeding. In most cases, medical management should be trialed prior to pursuing more invasive therapies.
- **Variant 5:** Hysterectomy is usually appropriate as a next step for a postmenopausal patient with uterine fibroids, symptomatic with heavy uterine bleeding or bulk symptoms (eg, pressure, pain, fullness, bladder, or bowel symptoms) and negative endometrial

biopsy. These procedures are equivalent alternatives (ie, only one procedure will be ordered to provide the clinical information to effectively manage the patient's care).

- **Variant 6:** Hysteroscopic myomectomy or laparoscopic or open myomectomy is usually appropriate for the initial therapy for a reproductive age patient with uterine fibroids desiring pregnancy and experiencing reproductive dysfunction. These procedures are equivalent alternatives (ie, only one procedure will be ordered to provide the clinical information to effectively manage the patient's care). The panel did not agree on recommending medical management for this clinical scenario. There is insufficient medical literature to conclude whether or not these patients would benefit from this procedure in this scenario. Intervention with this procedure in this patient population is controversial but may be appropriate.

SUPPORTING DOCUMENTS

The evidence table, literature search, and appendix for this topic are available at <https://acsearch.acr.org/list>. The appendix includes the strength of evidence assessment and the final rating round tabulations for each recommendation.

For additional information on the Appropriateness Criteria methodology and other supporting documents go to www.acr.org/ac.

REFERENCES

1. Ascher SM, Wasnik AP, Robbins JB, et al. ACR Appropriateness Criteria® fibroids. *J Am Coll Radiol* 2022;19:S319-28.
2. Kohn JR, Shamshirsaz AA, Popek E, Guan X, Belfort MA, Fox KA. Pregnancy after endometrial ablation: a systematic review. *BJOG* 2018;125:43-53.
3. Kim T, Purdy MP, Kendall-Rauchfuss L, et al. Myomectomy associated blood transfusion risk and morbidity after surgery. *Fertil Steril* 2020;114:175-84.
4. Laughlin-Tommaso SK, Lu D, Thomas L, et al. Short-term quality of life after myomectomy for uterine fibroids from the COMPARE-UF Fibroid Registry. *Am J Obstet Gynecol* 2020;222:345.e1-22.
5. Daniels J, Middleton LJ, Cheed V, et al. Uterine artery embolization or myomectomy for women with uterine fibroids: four-year follow-up of a randomised controlled trial. *Eur J Obstet Gynecol Reprod Biol X* 2022;13:100139.
6. Manyonda I, Belli AM, Lumsden MA, et al. Uterine-artery embolization or myomectomy for uterine fibroids. *N Engl J Med* 2020;383:440-51.
7. Casini ML, Rossi F, Agostini R, Unfer V. Effects of the position of fibroids on fertility. *Gynecol Endocrinol* 2006;22:106-9.
8. Jayaprakasan K, Polanski L, Sahu B, Thornton JG, Raine-Fenning N. Surgical intervention versus expectant management for endometrial polyps in subfertile women. *Cochrane Database Syst Rev* 2014;2014:CD009592.
9. Perez-Medina T, Bajo-Arenas J, Salazar F, et al. Endometrial polyps and their implication in the pregnancy rates of patients undergoing

- intrauterine insemination: a prospective, randomized study. *Hum Reprod* 2005;20:1632-5.
10. Litta P, Conte L, De Marchi F, Saccardi C, Angioni S. Pregnancy outcome after hysteroscopic myomectomy. *Gynecol Endocrinol* 2014;30:149-52.
11. Wise LA, Thomas L, Anderson S, et al. Route of myomectomy and fertility: a prospective cohort study. *Fertil Steril* 2022;117:1083-93.
12. Chen R, Su Z, Yang L, Xin L, Yuan X, Wang Y. The effects and costs of laparoscopic versus abdominal myomectomy in patients with uterine fibroids: a systematic review and meta-analysis. *BMC Surg* 2020;20:55.
13. de Bruijn AM, Ankum WM, Reekers JA, et al. Uterine artery embolization vs hysterectomy in the treatment of symptomatic uterine fibroids: 10-year outcomes from the randomized EMMY trial. *Am J Obstet Gynecol* 2016;215:745.e1-12.
14. Kim HS, Oh SY, Choi SJ, et al. Uterine rupture in pregnancies following myomectomy: a multicenter case series. *Obstet Gynecol Sci* 2016;59:454-62.
15. Mara M, Kubinova K, Maskova J, Horak P, Belsan T, Kuzel D. Uterine artery embolization versus laparoscopic uterine artery occlusion: the outcomes of a prospective, nonrandomized clinical trial. *Cardiovasc Intervent Radiol* 2012;35:1041-52.
16. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Gynecology. Management of symptomatic uterine leiomyomas: ACOG practice bulletin, Number 228. *Obstet Gynecol* 2021;137:e100-15.
17. Peitsidis P, Koukoulomati A. Tranexamic acid for the management of uterine fibroid tumors: a systematic review of the current evidence. *World J Clin Case* 2014;2:893-8.
18. Archer DF, Stewart EA, Jain RI, et al. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study. *Fertil Steril* 2017;108:152-60.e4.
19. Carr BR, Stewart EA, Archer DF, et al. Elagolix alone or with add-back therapy in women with heavy menstrual bleeding and uterine leiomyomas: a randomized controlled trial. *Obstet Gynecol* 2018;132:1252-64.
20. Hoshiai H, Seki Y, Kusumoto T, Kudou K, Tanimoto M. Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial. *BMC Womens Health* 2021;21:375.
21. Osuga Y, Enya K, Kudou K, Hoshiai H. Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women. *Fertil Steril* 2019;112:922-9.e2.
22. Schlaff WD, Ackerman RT, Al-Hendy A, et al. Elagolix for heavy menstrual bleeding in women with uterine fibroids. *N Engl J Med* 2020;382:328-40.
23. Simon JA, Al-Hendy A, Archer DF, et al. Elagolix treatment for up to 12 months in women with heavy menstrual bleeding and uterine leiomyomas. *Obstet Gynecol* 2020;135:1313-26.
24. de Milliano I, Huirne JAF, Thurkow AL, et al. Ulipristal acetate vs gonadotropin-releasing hormone agonists prior to laparoscopic myomectomy (MYOMEX trial): short-term results of a double-blind randomized controlled trial. *Acta Obstet Gynecol Scand* 2020;99:89-98.
25. Al-Hendy A, Lukes AS, Poindexter AN III, et al. Treatment of uterine fibroid symptoms with relugolix combination therapy. *N Engl J Med* 2021;384:630-42.
26. Liu JH, Soper D, Lukes A, et al. Ulipristal acetate for treatment of uterine leiomyomas: a randomized controlled trial. *Obstet Gynecol* 2018;132:1241-51.
27. Lukes AS, Soper D, Harrington A, et al. Health-related quality of life with ulipristal acetate for treatment of uterine leiomyomas: a randomized controlled trial. *Obstet Gynecol* 2019;133:869-78.
28. Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. *N Engl J Med* 2012;366:409-20.
29. Donnez J, Vazquez F, Tomaszewski J, et al. Long-term treatment of uterine fibroids with ulipristal acetate ? *Fertil Steril* 2014;101:1565-73.e1-18.
30. Osuga Y, Nakano Y, Yamauchi Y, Takanashi M. Ulipristal acetate compared with leuprolerin acetate for Japanese women with symptomatic uterine fibroids: a phase III randomized controlled trial. *Fertil Steril* 2021;116:189-97.
31. Gatti M, Poluzzi E, De Ponti F, Raschi E. Liver injury with ulipristal acetate: exploring the underlying pharmacological basis. *Drug Saf* 2020;43:1277-85.
32. Yoon EL, Yuk JS. Use of ulipristal acetate and risk of liver disease: a nationwide cohort study. *J Clin Endocrinol Metab* 2021;106:1773-82.
33. Sridhar D, Kohi MP. Updates on MR-guided focused ultrasound for symptomatic uterine fibroids. *Semin Intervent Radiol* 2018;35:17-22.
34. Jacoby VL, Kohi MP, Poder L, et al. PROMISe trial: a pilot, randomized, placebo-controlled trial of magnetic resonance guided focused ultrasound for uterine fibroids. *Fertil Steril* 2016;105:773-80.
35. Laughlin-Tommaso S, Barnard EP, Abdelmagied AM, et al. FIRSTT study: randomized controlled trial of uterine artery embolization vs focused ultrasound surgery. *Am J Obstet Gynecol* 2019;220:174.e1-13.
36. Barnard EP, Abdelmagied AM, Vaughan LE, et al. Periprocedural outcomes comparing fibroid embolization and focused ultrasound: a randomized controlled trial and comprehensive cohort analysis. *Am J Obstet Gynecol* 2017;216:500.e1-11.
37. Chen J, Li Y, Wang Z, et al. Evaluation of high-intensity focused ultrasound ablation for uterine fibroids: an IDEAL prospective exploration study. *BJOG* 2018;125:354-64.
38. Gorny KR, Borah BJ, Brown DL, Woodrum DA, Stewart EA, Hesley GK. Incidence of additional treatments in women treated with MR-guided focused US for symptomatic uterine fibroids: review of 138 patients with an average follow-up of 2.8 years. *J Vasc Interv Radiol* 2014;25:1506-12.
39. Froeling V, Meckelburg K, Schreiter NF, et al. Outcome of uterine artery embolization versus MR-guided high-intensity focused ultrasound treatment for uterine fibroids: long-term results. *Eur J Radiol* 2013;82:2265-9.
40. Mohr-Sasson A, Machtinger R, Mashiach R, et al. Long-term outcome of MR-guided focused ultrasound treatment and laparoscopic myomectomy for symptomatic uterine fibroid tumors. *Am J Obstet Gynecol* 2018;219:375.e1-7.
41. Rabinovici J, David M, Fukunishi H, et al. Pregnancy outcome after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for conservative treatment of uterine fibroids. *Fertil Steril* 2010;93:199-209.
42. Ananthakrishnan G, Murray L, Ritchie M, et al. Randomized comparison of uterine artery embolization (UAE) with surgical treatment in patients with symptomatic uterine fibroids (REST trial): subanalysis of 5-year MRI findings. *Cardiovasc Intervent Radiol* 2013;36:676-81.
43. Liu L, Wang T, Lei B. Uterine artery embolization compared with high-intensity focused ultrasound ablation for the treatment of symptomatic uterine myomas: a systematic review and meta-analysis. *J Minim Invasive Gynecol* 2021;28:218-27.
44. Torre A, Fauconnier A, Kahn V, Limot O, Bussierrres L, Pelage JP. Fertility after uterine artery embolization for symptomatic multiple fibroids with no other infertility factors. *Eur Radiol* 2017;27:2850-9.
45. Serres-Cousine O, Kuijper FM, Curis E, Atashroo D. Clinical investigation of fertility after uterine artery embolization. *Am J Obstet Gynecol* 2021;225:403.e1-22.
46. Pisco JM, Duarte M, Bilhim T, et al. Spontaneous pregnancy with a live birth after conventional and partial uterine fibroid embolization. *Radiology* 2017;285:302-10.
47. Mara M, Maskova J, Fucikova Z, Kuzel D, Belsan T, Sosna O. Midterm clinical and first reproductive results of a randomized controlled trial comparing uterine fibroid embolization and myomectomy. *Cardiovasc Intervent Radiol* 2008;31:73-85.

48. Jain P, Rajaram S, Gupta B, Goel N, Srivastava H. Randomized controlled trial of thermal balloon ablation versus vaginal hysterectomy for leiomyoma-induced heavy menstrual bleeding. *Int J Gynaecol Obstet* 2016;135:140-4.
49. Ibiebele I, Nippita TA, Baber R, Torvaldsen S. A study of pregnancy after endometrial ablation using linked population data. *Acta Obstet Gynecol Scand* 2021;100:286-93.
50. Stewart EA, Laughlin-Tommaso SK, Catherino WH, Lalitkumar S, Gupta D, Vollenhoven B. Uterine fibroids. *Nat Rev Dis Primers* 2016;2:16043.
51. Laughlin-Tommaso SK, Khan Z, Weaver AL, Smith CY, Rocca WA, Stewart EA. Cardiovascular and metabolic morbidity after hysterectomy with ovarian conservation: a cohort study. *Menopause* 2018;25:483-92.
52. Laughlin-Tommaso SK, Satish A, Khan Z, Smith CY, Rocca WA, Stewart EA. Long-term risk of de novo mental health conditions after hysterectomy with ovarian conservation: a cohort study. *Menopause* 2020;27:33-42.
53. Tuesley KM, Protani MM, Webb PM, et al. Hysterectomy with and without oophorectomy and all-cause and cause-specific mortality. *Am J Obstet Gynecol* 2020;223:723.e1-16.
54. Ruuskanen A, Hippelainen M, Sipola P, Manninen H. Uterine artery embolisation versus hysterectomy for leiomyomas: primary and 2-year follow-up results of a randomised prospective clinical trial. *Eur Radiol* 2010;20:2524-32.
55. Yeh YT, Li PC, Wu KC, et al. Hysterectomies are associated with an increased risk of osteoporosis and bone fracture: a population-based cohort study. *PLoS One* 2020;15:e0243037.
56. Rocca WA, Grossardt BR, Shuster LT, Stewart EA. Hysterectomy, oophorectomy, estrogen, and the risk of dementia. *Neurodegener Dis* 2012;10:175-8.
57. Aarts JW, Nieboer TE, Johnson N, et al. Surgical approach to hysterectomy for benign gynaecological disease. *Cochrane Database Syst Rev* 2015;2015:CD003677.
58. Albright BB, Witte T, Tofte AN, et al. Robotic versus laparoscopic hysterectomy for benign disease: a systematic review and meta-analysis of randomized trials. *J Minim Invasive Gynecol* 2016;23:18-27.
59. Mengerink BB, van der Wurff AA, ter Haar JF, van Rooij IA, Pijnenborg JM. Effect of undiagnosed deep adenomyosis after failed NovaSure endometrial ablation. *J Minim Invasive Gynecol* 2015;22:239-44.
60. Fraser IS, Romer T, Parke S, et al. Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind phase III trial. *Hum Reprod* 2011;26:2698-708.
61. Jensen JT, Parke S, Mellinger U, Machlitt A, Fraser IS. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. *Obstet Gynecol* 2011;117:777-87.
62. Shaaban MM, Zakherah MS, El-Nashar SA, Sayed GH. Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial. *Contraception* 2011;83:48-54.
63. Shaaban OM, Ali MK, Sabra AM, Abd El Aal DE. Levonorgestrel-releasing intrauterine system versus a low-dose combined oral contraceptive for treatment of adenomyotic uteri: a randomized clinical trial. *Contraception* 2015;92:301-7.
64. Muneyirci-Delale O, Archer DF, Owens CD, et al. Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis. *F S Rep* 2021;2:338-46.
65. Froeling V, Scheurig-Muenkler C, Hamm B, Kroencke TJ. Uterine artery embolization to treat uterine adenomyosis with or without uterine leiomyomata: results of symptom control and health-related quality of life 40 months after treatment. *Cardiovasc Intervent Radiol* 2012;35:523-9.
66. de Bruijn AM, Smink M, Hehenkamp WJK, et al. Uterine artery embolization for symptomatic adenomyosis: 7-year clinical follow-up using UFS-QOL questionnaire. *Cardiovasc Intervent Radiol* 2017;40:1344-50.
67. Smeets AJ, Nijenhuis RJ, Boekkooi PF, Vervest HA, van Rooij WJ, Lohle PN. Long-term follow-up of uterine artery embolization for symptomatic adenomyosis. *Cardiovasc Intervent Radiol* 2012;35:815-9.
68. de Bruijn AM, Smink M, Lohle PNM, et al. Uterine artery embolization for the treatment of adenomyosis: a systematic review and meta-analysis. *J Vasc Interv Radiol* 2017;28:1629-1624.e1.
69. de Bruijn AM, Lohle PN, Huirne JA, et al. Uterine artery embolization versus hysterectomy in the treatment of symptomatic adenomyosis: protocol for the randomized QUESTA trial. *JMIR Res Protoc* 2018;7:e47.
70. Nguyen MD. Magnetic resonance imaging-guided volumetric high-intensity focused ultrasound surgery for pedunculated subserosal uterine leiomyoma. *Gynecol Minim Invasive Ther* 2020;9:104-5.
71. Park H, Yoon SW, Kim KA, Jung Kim D, Jung SG. Magnetic resonance imaging-guided focused ultrasound treatment of pedunculated subserosal uterine fibroids: a preliminary report. *J Vasc Interv Radiol* 2012;23:1589-93.
72. Smeets AJ, Nijenhuis RJ, Boekkooi PF, et al. Safety and effectiveness of uterine artery embolization in patients with pedunculated fibroids. *J Vasc Interv Radiol* 2009;20:1172-5.
73. Radeleff B, Eiers M, Bellemann N, et al. Expulsion of dominant submucosal fibroids after uterine artery embolization. *Eur J Radiol* 2010;75:e57-63.
74. Lee SJ, Kim MD, Kim GM, Won JY, Park SI, Lee DY. Uterine artery embolization for symptomatic fibroids in postmenopausal women. *Clin Imaging* 2016;40:106-9.
75. Brohl AS, Li L, Andikyan V, et al. Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma. *Oncologist* 2015;20:433-9.
76. Ulin M, Ali M, Chaudhry ZT, Al-Hendy A, Yang Q. Uterine fibroids in menopause and perimenopause. *Menopause* 2020;27:238-42.
77. Palomba S, Zupi E, Russo T, et al. A multicenter randomized, controlled study comparing laparoscopic versus minilaparotomic myomectomy: short-term outcomes. *Fertil Steril* 2007;88:942-51.
78. Seracchioli R, Rossi S, Govoni F, et al. Fertility and obstetric outcome after laparoscopic myomectomy of large myomata: a randomized comparison with abdominal myomectomy. *Hum Reprod* 2000;15:2663-8.
79. Morgante G, Centini G, Troia L, Orvieto R, De Leo V. Ulipristal acetate before in vitro fertilization: efficacy in infertile women with submucous fibroids. *Reprod Biol Endocrinol* 2020;18:50.
80. Hanstede MM, Tempany CM, Stewart EA. Focused ultrasound surgery of intramural leiomyomas may facilitate fertility: a case report. *Fertil Steril* 2007;88:497.e5-7.
81. Zaher S, Lyons D, Regan L. Uncomplicated term vaginal delivery following magnetic resonance-guided focused ultrasound surgery for uterine fibroids. *Biomed Imaging Interv J* 2010;6:e28.
82. Bouwsma EV, Gorny KR, Hesley GK, Jensen JR, Peterson LG, Stewart EA. Magnetic resonance-guided focused ultrasound surgery for leiomyoma-associated infertility. *Fertil Steril* 2011;96:e9-12.